Bioequivalence and Bioavailability Forum 20:53 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Disturbing wording [Dissolution / BCS / IVIVC]

posted by ElMaestro - Denmark, 2017-12-25 18:28  - Posting: # 18081
Views: 2,027

Hi all,

re. FDA's new biowaiver guidance Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System:

I do absolutely not like this sentence on page 8 re. the calculation of f2:
"Two dissolution profiles are considered similar when the f2 value is ≥ 50. To allow the use of mean data, the coefficient of variation should not be more than (...)"

If taken verbatim this means that an f2-based method is not acceptable when the CV is high, full stop. In that case I believe there's just the Mahalanobis distance left as a semi-bad proposal for a way forward.
I think and hope they meant something like "Two dissolution profiles are considered similar when the f2 value is ≥ 50. To allow the use of the plain f2 as a measure of similarity of dissolution profiles, the coefficient of variation should not be more than (...)"
- this would keep the door open for bootstrapping which was what was done internally at FDA for the now slightly famous Mesalamine case.

Goodbye to bootstrapping or just a little snafu when they wrote the draft?

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,783 posts in 4,003 threads, 1,258 registered users;
online 10 (0 registered, 10 guests [including 8 identified bots]).

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed